Pfizer expands hemophilia gene therapy pipeline with $720m Sangamo deal – BioPharma-Reporter.com
BioWorld Online |
Pfizer expands hemophilia gene therapy pipeline with $720m Sangamo deal
BioPharma-Reporter.com The agreement sees Pharma giant Pfizer pay Sangamo $70m upfront, but the Californian genome editing firm could receive up to $475m in milestone payments for its lead haemophilia A gene therapy SB-525, and a further $175m for other candidates … Pfizer top hemophilia choice, enters Sangamo pact that is valued to $500M-plus |
